大环内酯类药物使用是否存在耐药阈值？来自[具体地区1]、[具体地区2]和[具体地区3]耐药数据的生态学分析的肯定证据。
Is There a Resistance Threshold for Macrolide Consumption? Positive Evidence from an Ecological Analysis of Resistance Data from , and .
作者信息
Kenyon Chris, Manoharan-Basil Sheeba S, Van Dijck Christophe
机构信息
HIV/STI Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Department of Medicine, Division of Infectious Diseases and HIV Medicine, University of Cape Town, Cape Town, South Africa.
出版信息
Microb Drug Resist. 2021 Aug;27(8):1079-1086. doi: 10.1089/mdr.2020.0490. Epub 2021 Feb 16.
If we were to keep macrolide consumption below a certain threshold, would this reduce the probability of macrolide resistance emerging? No study that we are aware of has addressed this question. We, therefore, assessed at a country level if there was a macrolide consumption threshold for the selection of a prevalence of macrolide resistance of over 5% in , , and . In this ecological-level analysis, we found evidence for a macrolide consumption threshold of 1.3 defined daily doses per 1,000 inhabitants per day (DID) for , 1.8 DID for , and 2.3 DID for . Our results provide further motivation for macrolide stewardship campaigns that strive to reduce macrolide consumption to levels below at least 2 DID.
如果我们将大环内酯类药物的消费量控制在某个阈值以下，这是否会降低大环内酯类耐药性出现的概率？据我们所知，尚无研究探讨过这个问题。因此，我们在国家层面评估了在[具体地区1]、[具体地区2]和[具体地区3]中，是否存在一个大环内酯类药物消费阈值，以选择大环内酯类耐药率超过5%的情况。在这项生态学水平分析中，我们发现，对于[具体地区1]，大环内酯类药物消费阈值为每天每1000名居民1.3限定日剂量（DID）；对于[具体地区2]，为1.8 DID；对于[具体地区3]，为2.3 DID。我们的结果为大环内酯类药物管理活动提供了进一步的动力，这些活动致力于将大环内酯类药物的消费量降低到至少2 DID以下的水平。
Zotero 插件